Author

Masoud Aliyar

Golestan University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioinformatics· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Approach:machine learning (classical)· 1 Approach:simulation· 1 Approach:statistical model· 1

Frequent Co-Authors

Hassan AryapouriD· 3 shared Farzin SohrabyiD· 2 shared Mostafa Javaheri MoghadamiD· 2 shared Majid MahdaviiD· 1 shared Milad Jaberi· 1 shared Mosleh KadkhodamohammadiiD· 1 shared Reza Babaei akerdi· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

7 top collaborators · 7 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioinformatics

Hassan AryapourORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A boosted unbiased molecular dynamics method for predicting ligands binding mechanisms: Probing the binding pathway of dasatinib to Src-kinase

Farzin Sohraby, Mostafa Javaheri Moghadam, Masoud Aliyar, Hassan Aryapour

This paper presents a method to perform unbiased molecular dynamics simulations on desktop computers to study ligand binding pathways, demonstrating dasatinib's binding to Src-kinase without biasing forces.

Bioinformatics · Jun 5, 2020Peer-reviewedBioinformatics

Complete reconstruction of the unbinding pathway of an anticancer drug by conventional unbiased molecular dynamics simulation

Farzin Sohraby, Mostafa Javaheri Moghadam, Masoud Aliyar, Hassan Aryapour

This study uses molecular dynamics simulations to reconstruct the unbinding pathway of dasatinib from c-Src kinase without applying biases, achieving complete unbinding in 392.6 ns.

bioRxiv · Feb 23, 2020 · PreprintBioinformatics

Identification of new inhibitors of the Toxoplasma gondii by using in-silico drug repurposing

Mosleh Kadkhodamohammadi, Milad Jaberi, Reza Babaei akerdi, Masoud Aliyar

This study identifies FDA-approved drugs that can inhibit Toxoplasma gondii's Calcium-Dependent Protein Kinase 1 through in-silico methods, suggesting potential new treatments for toxoplasmosis.

bioRxiv · Aug 13, 2019 · PreprintBioinformatics

In-silico predictive identification of K-RasG12V inhibitors in natural compounds

Masoud Aliyar, Hassan Aryapour, Majid Mahdavi

The paper identifies potential K-RasG12V inhibitors from natural compounds using structure-based drug design and molecular dynamics simulations.

bioRxiv · Feb 18, 2019 · PreprintBioinformatics